Impact Naturals

CHYLOSOMA™ DRUG DELIVERY - A whole new way of delivering poorly soluble oral drugs. By NATURALLY ENCAPSULATING ORAL DRUGS IN CHYLOMICRONS, we avoid liver metabolism and better target delivery to the body’s tissues. ORAL DELIVERY WITH PARENTERAL EFFICIENCY: Encapsulation of parenteral drugs is an established method of improving efficacy and safety, e.g, Abraxane, Vyxeos, and COVID-19 mRNA vaccines. The CHYLOSOMA™ platform facilitates the natural encapsulation of orally administered molecules in chylomicrons, mimicking encapsulated IV delivery systems (Chylomicrons are the only transport carriers of dietary fats in the blood). REDEFINING THE PROCESS OF DELIVERY OPTIMIZATION-Predictive method to select and validate formulations prior to clinical development-Development engine for discovering proprietary formulation components-An artificial intelligence engine will be used to create an in-silico system for formulation development-Establish a new standard of PK assessment. FIRST AND ONLY FORMULATION SCREENING SYSTEM USING A PHYSIOLOGICAL ENDPOINT. Founded in 2019, Impact Naturals has applied our deep experience from the pharmaceutical, biotech, and research sciences to create a patented delivery technology called CHYLOSOMA™ focused on using lipoproteins for oral delivery of pharmaceuticals and supplements. CHYLOSOMA™ is the result of over 30 years of research to create a better, more complete understanding of lipid transport systems. CHYLOSOMA™ Assay Unlocks Potential of Lymphatic Absorption and Chylomicron Drug Delivery-Accurately measure lymphatic vs. portal absorption and trafficking from the gut-Eliminate the need to perform complex microsurgery – the only existing way to measure lymphatic absorption and delivery. POTENTIAL BENEFITS -Shows high active ingredient levels relative to standard PK studies -Improvement of efficacy -Improvement of safety profile -More convenient dosing -Eliminate Food Effect -Expanded indication(s)-Lower COGs